Breast Neoplasms  >>  Perjeta (pertuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perjeta (pertuzumab) / Roche
NCT02491892: A Study of Pertuzumab in Participants With Metastatic Breast Cancer

Completed
2
79
Europe, RoW
Pertuzumab, rhuMAb 2C4
Hoffmann-La Roche
Breast Cancer
04/05
04/05
NCT01674062 / 2005-003493-19: A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Completed
2
95
Canada, Europe
Pertuzumab, Perjeta, Trastuzumab, Herceptin
Hoffmann-La Roche
Breast Cancer
02/08
09/15
NCT00943670: Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Completed
2
51
US
pertuzumab, PERJETA™, Trastuzumab emtansine [Kadcyla], trastuzumab-MCC-DM1, T-DM1
Genentech, Inc.
Metastatic Breast Cancer
12/10
08/11
TRYPHAENA, NCT00976989 / 2009-012019-17: A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Checkmark
May 2013 - May 2013: 
Checkmark SG-BCC 2013
Mar 2013 - Mar 2013: SG-BCC 2013
Checkmark P2 data - ESMO
More
Completed
2
225
Canada, Europe, RoW
Pertuzumab, Perjeta, Trastuzumab, Herceptin, FEC, Docetaxel, TCH
Hoffmann-La Roche
Breast Cancer
06/11
01/16
NeoSphere, NCT00545688 / 2007-001105-13: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Checkmark NEOSPHERE trial in neoadjuvant breast cancer at ASCO 2015
May 2015 - Jun 2015: NEOSPHERE trial in neoadjuvant breast cancer at ASCO 2015
Checkmark Final PFS/DFS data from NEOSPHERE trial in neoadjuvant BC at ASCO 2015
May 2015 - May 2015: Final PFS/DFS data from NEOSPHERE trial in neoadjuvant BC at ASCO 2015
Checkmark For HER2 positive breast cancer in neoadjuvant setting
More
Completed
2
417
Canada, Europe, RoW
Herceptin, Trastuzumab, Docetaxel, Pertuzumab
Hoffmann-La Roche
Breast Cancer
09/14
09/14
NCT01565083 / 2011-003308-18: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Checkmark EBCC 2014
Mar 2014 - Mar 2014: EBCC 2014
Completed
2
213
US, Europe, RoW
Pertuzumab, Perjeta, Trastuzumab, Herceptin, Vinorelbine
Hoffmann-La Roche
Breast Cancer
10/15
10/15
NCT01912963: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Terminated
2
32
US
Pertuzumab, Perjeta, Trastuzumab, Herceptin, eribulin, eribulin mesylate, Halaven
Dana-Farber Cancer Institute, Eisai Inc., Genentech, Inc.
HER2-positive Breast Cancer, Metastatic Breast Cancer
12/16
12/16
NCT00875979 / 2008-008276-14: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Checkmark In combination with pertuzumab in pts with HER2+ve, locally adv/mets BC
Apr 2014 - Apr 2014: In combination with pertuzumab in pts with HER2+ve, locally adv/mets BC
Checkmark Data
Jun 2010 - Jun 2010: Data
Completed
1/2
67
US, Canada, Europe
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg, Perjeta
Hoffmann-La Roche, Roche Pharma AG
Metastatic Breast Cancer
08/11
08/11
NCT00951665: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Pooled P1 data
Dec 2011 - Dec 2011: Pooled P1 data
Completed
1/2
107
US
paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
Genentech, Inc.
Metastatic Breast Cancer
02/12
06/13
NCT00934856 / 2009-010000-28: A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Pooled P1 data
Dec 2011 - Dec 2011: Pooled P1 data
Completed
1/2
98
US, Europe
Docetaxel, Pertuzumab, Trastuzumab emtansine, T-DM1
Hoffmann-La Roche
Breast Cancer
10/13
10/13

Download Options